

***Lactobacillus acidophilus* disrupts collaborative multispecies bile acid metabolism**

Sydney Dautel^{1,2}, Nymul Khan¹, Kristoffer R. Brandvold¹, Colin J. Brislawn¹, Janine Hutchison³, Karl K. Weitz¹, Heino M. Heyman¹, Hyun-Seob Song¹, Zehra Esra Ilhan⁴, Eric A. Hill¹, Joshua R. Hansen¹, Xueyun Zheng¹, Erin S. Baker¹, John R. Cort¹, Young-Mo Kim¹, Nancy G. Isern⁵, John K. DiBaise⁶, Rosa Krajmalnik-Brown⁴, Janet K. Jansson¹, Aaron T. Wright^{1,7}, Thomas O. Metz¹, Hans C. Bernstein^{1,7,8*}

Affiliations:

¹Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA; ²School of Medicine, University of Washington, Seattle, WA, USA; ³Chemical and Biological Signature Science, Pacific Northwest National Laboratory, Richland, WA, USA; ⁴Biodesign Swette Center for Environmental Biotechnology and Biodesign Center for Fundamental and Applied Microbiomics, Arizona State University, Tempe, AZ, USA; ⁵Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, USA; ⁶Division of Gastroenterology, Mayo Clinic, Scottsdale, AZ, USA; ⁷The Gene and Linda Voiland School of Chemical Engineering and Bioengineering, Washington State University, Pullman, WA, USA; ⁸Norwegian College of Fishery Science, UiT - The Arctic University of Norway, 9019, Tromsø, Norway

***Correspondence:** Hans C. Bernstein, 902 Battelle Boulevard, P.O. Box 999, MSIN J4-18, Richland WA, 99352; Phone: 509-371-6989, Email: Hans.Bernstein@pnnl.gov; Email: Hans.C.Bernstein@uit.no

Keywords: probiotic, bile acid, microbiome, consortia, multi-omics, chemical probes

ABSTRACT

Bile acids are metabolic links between hosts and their gut microbiomes, yet little is known about the roles they play in microbe-to-microbe interactions. Here we present a study designed to investigate the effect that a common probiotic, *Lactobacillus acidophilus*, has on microbial interactions that lead to formation of secondary bile acids. A model microbial consortium was built from three human gut isolates, *Clostridium scindens*, *Collinsella aerofaciens*, and *Blautia obeum*, and cultured under different bile acid and probiotic treatments. A multi-omics platform that included mass spectrometry-based metabolomics and activity-based proteomic probes was used to produce two major results. The first, was that an uncommon secondary bile acid – ursocholate – was produced by a multi-species chemical synthesis pathway. This result highlights a new microbe-to-microbe interaction mediated by bile acids. The second finding was that the probiotic strain, *L. acidophilus*, quenched the observed interactions and effectively halted consortial synthesis of ursocholate. Little is known about the role that ursocholate plays in human health and development. However, we did discover that a decrease in ursocholate abundance corresponded with successful weight loss in patients after gastric bypass surgery versus those who did not lose weight after surgery. Hence, this study uncovered basic knowledge that may aid future designs of custom probiotic therapies to combat obesity.

INTRODUCTION

The human gastrointestinal (GI) tract is a complex ecosystem that functions in symbiosis with oral and intestinal microbiomes^{1,2}. It has long been recognized that the composition of the gut microbiome has a significant effect on host digestion but more recent research has implicated the microbiome in human health and disease states that include cardiovascular disease risk³, neurological function⁴, and autoimmunity⁵. Rapid gains in knowledge of host-microbiome associations will undoubtedly lead to new practical applications⁶. Of these, the use of probiotics to modulate both the function and composition of gut microbiomes is especially promising^{7,8}. Probiotic supplementation likely reduces the risk of developing antibiotic associated diarrhea⁹ and necrotizing enterocolitis in infants¹⁰. However, the therapeutic opportunities for probiotics are advancing to more precisely target specific processes carried out by the gut microbiome to impart health benefits beyond enhanced digestion¹¹⁻¹³. Probiotic therapies are being explored to relieve symptoms of autism¹⁴, depression⁴, autoimmune diseases^{15,16}, and irritable bowel syndrome¹⁷ among many other conditions with positive – albeit conflicting – results. The efficacy of probiotic treatments is variable. Differing results can obviously arise from inconsistent study design – e.g., probiotic strain, dose – trial size, but they are also indicative of a large scientific knowledge gap and incomplete understanding of the mechanisms by which probiotics impact the GI-tract microbial ecosystem.

There are many hypotheses about the modes of action by which the gut microbiome and probiotic microbes impact human health. One proposed model is through modulation of the host immune system¹⁸, which has been concluded from studies that showed probiotic treatments affecting host immune function in humans facing pathogenic challenges¹⁹⁻²¹ or with autoimmune disorder^{15,16,22}. Another hypothesis is that probiotics increase microbial competition within the

intestinal ecosystem, thereby making it more difficult for pathogenic bacteria to survive^{23,24}. Studies have also speculated that observed therapeutic action from probiotics results from their effect on the intestinal physiology by modulating endothelial junctions²⁵ and the mucosal lining^{12,25} through a variety of proposed metabolic pathways. Another possible mode of action for probiotics is through bile acids. It has long been known that bile acids are important linkers between host and gut microbes. Intestinal bacteria produce secondary bile acids by deconjugation, reduction, oxidation, and epimerization of their host's primary bile acids. Many probiotics can alter bile acid pools in humans^{26,27}.

The primary bile acids (cholic acid and chenodeoxycholic acid) are synthesized in human hepatocytes and conjugated to the amino acids glycine and taurine to increase solubility^{27,28}. They are then released into the duodenum and moved through the small intestine to assist emulsification of dietary lipophilic substances²⁹. Approximately 95% of the bile acids are then passively reabsorbed in transit through the small intestine, resulting in approximately 5% (400-800 mg) passed on to the colon²⁷. In the colon, these bile acids are rapidly deconjugated by the microbiome and reduced, oxidized and epimerized to a variety of secondary bile acids²⁷. These secondary bile acids are known to have diverse effects on human health ranging from direct cytotoxicity³⁰, to altered probability of cancer³¹, to hormonal function as cell messengers^{29,32-34}. More recently, this list of known host-related effects has grown to include modulating the composition and function of the gut microbiome^{35,36} – e.g., by disassembling lipid membranes.

The intestinal microbiome represents a major modifier of the human bile acid pool. This is evinced by the fact that bile in the gall bladder is comprised of 70% primary bile acids but only 4% primary bile acids in the feces²⁷. Not only does the microbiome determine bile acid composition, but bile acids also direct microbial communities³⁷. For example, studies have

shown that high fat diets and diets high in resistant starch³⁸ have an effect on both the bile acid pool³⁹ and the microbiome⁴⁰. It has also been shown in rats that oral administration of certain bile acids can shift the microbiome composition^{35,41}. Collectively, these studies suggest that there is a complex interplay between microbial species and bile acids that is not fully understood.

The relationships between the gut microbiome, probiotics and the bile acid pool are particularly relevant due to the current epidemic of obesity and the comorbidities associated with high adiposity (high cholesterol, high blood pressure, diabetes)⁴². Due to high rates of obesity, bariatric surgery has become a more common procedure with the number and types of surgeries increasing with time^{43,44}. It is now well established that bariatric surgery results in reduced weight and a reduction in many comorbidities of obesity⁴⁵. Several different advantages (weight loss, reduction of comorbidity) and disadvantages (surgical complications, malnutrition, weight regain, re-surgery, infection, etc.)^{45,46} have been identified for different bariatric procedures. Yet, there remains an incomplete understanding of the exact mechanisms of many of these outcomes, making it difficult to predict which patients will benefit most from these procedures. Elucidation of the root causes will require consideration of the impacts that the bile acid pool, microbiome composition and probiotic administration can have^{47,48}. Deeper mechanistic insight could not only result in increased surgery success, potentially by pre-emptive modulation of the microbiome by bile acid pool^{49,50}, but could also result in less surgeries necessitated if some of the positive results can indeed be realized via targeted use of probiotics.

Here we present a study that was designed to investigate the community dynamics of microbes commonly found in the gut and the impact that both the addition of bile acids and a probiotic has on interspecies interactions. An *in vitro* model was built as a three-species bacterial consortium, *Clostridium scindens*, *Collinsella aerofaciens*, and *Blautia obeum*, each of which

occurs naturally in the human gut. This consortium was then treated with the probiotic strain *Lactobacillus acidophilus* to make an altered four-member consortium. Multi-omics assays were used to elucidate the interspecies microbial interactions with and without bile acid treatments (cholic acid and deoxycholic acid). We found that a secondary bile acid, ursocholic acid (7-epicholic acid), was produced from cholic acid through a multispecies chemical synthesis route mediated by an interaction between *B. obeum* and *C. aerofaciens*. This process was quenched by the addition of *L. acidophilus*, which disrupted the coordination between *B. obeum* and *C. aerofaciens* and shut down ursocholic acid production. These results were then contextualized by performing targeted metabolite measurements in fecal samples from a human clinical study⁴⁴ that investigated secondary bile acid abundances as outcomes of gastric bypass surgery. The abundance of ursocholic acid corresponded with successful post-operative weight loss, highlighting that it may be important to investigate the implications of both patient- and microbe-derived metabolites to help gain a predictive understanding of a patient's response to bariatric surgery. New knowledge in this area will yield opportunities to design custom probiotic therapies. More broadly, this study supports an emerging theme in microbiome sciences that microbial interactions are context dependent and the presence or absence of select species and/or metabolites can have a strong effect on the overall function.

RESULTS

A model microbial consortium responds to probiotic and bile acid treatments. We constructed an *in vitro* microbial consortium from human gut bacterial isolates. A 3-member consortium (3MC) composed of *Clostridium scindens* ATCC 35704, *Collinsella aerofaciens* ATCC 25986, and *Blautia obeum* ATCC 29174 was compared to a 4-member consortium (3MC

+ L) that included an added a probiotic strain, *Lactobacillus acidophilus* ATCC 4356. The species were chosen for this model based on their capacity to perform one-of-three unique microbial transformations on human bile acids (Table S1): 7 α -dehydroxylation, hydroxysteroid dehydrogenation, or bile salt hydrolysis^{27,37,51,52}.

Anaerobic culturing treatments included supplementation with cholic acid and/or deoxycholic acid and were compared to axenic controls. We found that each member of the consortia grew together under anaerobic culturing conditions but that each consortium (3MC versus 3MC + L) had very different growth and extracellular metabolite profiles (Fig. 1). Despite the anticipated anti-microbial effect of bile acids^{26,53,54}, all cultures in media containing added cholic acid and deoxycholic acid (0.1 mM) showed faster specific growth rates compared to their corresponding treatments without bile acids (Fig. 1a and b). The axenic controls confirmed that *L. acidophilus* had the fastest specific growth rate, followed by *B. obeum*, *C. aerofaciens* and *C. scindens*. The probiotic, *L. acidophilus*, was the least affected by the addition of the bile acids to the growth media, with only a 17% increase in the specific growth rate as compared to 170%, 76% and 167% increases for *C. scindens*, *C. aerofaciens* and *B. obeum*, respectively. An adonis test was used to show that the species composition of each consortium – i.e., presence/absence of *L. acidophilus* – was the strongest determiner of variance ($R^2 = 0.49$, $p < 0.001$) in the extracellular metabolome. This was in contrast to the effect of treatments that tested for changes in the global metabolome based on bile acid or no bile acid inputs, which were not a statistically significant source of variance (Fig. 1C). Hence, the probiotic *L. acidophilus* was a major modifier of the extracellular chemical environment.




Figure 1. Probiotic influence on consortial growth and the extracellular chemical environment. (A) Growth of the 3-member consortium (3MC) in bile acid supplemented media as compared to (B) the 4-member consortium (3MC + L) that differed by the addition of probiotic, *L. acidophilus*. The y-axis of A and B represent means from triplicate measurements of absolute species abundance defined as the total optical density (OD_{630nm}) at each time point multiplied by each respective measurement of relative abundance obtained from qPCR; error bars represent ± 1 standard deviation. (C) A principle component analysis on the extracellular metabolome ordinated by the Euclidean distance between the metabolic profiles from each treatment. The colored ellipses represent 95% confidence limits assuming a multi-variate t-distribution.

***L. acidophilus* quenches secondary bile acid production.** Ursocholic acid was produced in the 3MC (Fig. 2A), but not by any one species grown under axenic conditions. Hence, ursocholic acid was produced by a multispecies synthesis route that required at least two species from our model consortium. Addition of the probiotic, *L. acidophilus* quenched the production of

ursocholic acid to negligible levels as compared to those measured in the 3MC (Fig. 2b). In addition to ursocholic acid production, *L. acidophilus* also attenuated growth of *B. obeum* and *C. aerofaciens* as observed in the 3MC + L species-specific growth dynamics, which were in stark contrast to the 3MC (Fig. 2c). Within the 3MC + L, *L. acidophilus* became a dominant member of the community, but in the absence of the probiotic, the 3MC was dominated by *B. obeum* with *C. scindens* showing the lowest relative abundance in both consortia.

The dynamic profiles of bile acids and bacterial species were correlated for each treatment group, 3MC and 3MC + L (Fig. 2d), respectively. Pearson's correlations were determined between species and for species to bile acids but not between bile acids. The results show that ursocholic acid shared strong positive correlations (Pearson's coefficient; $r > 0.85$) with the abundances of *C. aerofaciens* and *B. obeum* in the 3MC. As expected, cholic acid showed strong negative correlations with *C. aerofaciens* and *B. obeum* within the 3MC, establishing that it was the most likely substrate for ursocholic acid synthesis. Cholic acid, was not correlated with *C. scindens*, implying that this species may not have been involved in production of secondary bile acids directly from cholic acid. The lack of *C. scindens*' participation in secondary bile acid synthesis in the 3MC was also evinced by its strong negative correlation with deoxycholic acid, a known 7α -dehydroxylation product of *C. scindens* that utilizes cholic acid as the substrate²⁷.

L. acidophilus membership changed the correlations between species and bile acids. Most notably, ursocholic acid was not correlated with any species in the 3MC + L under the probiotic treatment. *L. acidophilus* did not correlate with any of the bile acids and shared strong negative correlations with *C. aerofaciens* and *B. obeum*, indicating that competition and/or antagonism are the likely mechanisms by which the multi-species ursocholic acid synthesis was quenched.

Multispecies synthesis of ursocholic acid. Based on the metabolomics results, we hypothesized a multi-species cooperative synthesis of ursocholic acid that involved both *B.*

obeum and *C. aerofaciens*. The initial inference was derived by comparing the metabolite




Figure 2. Secondary bile acid – ursocholic acid – was produced by consortia but not axenic cultures; *L. acidophilus* disrupted the consortial synthesis. (A) Comparative abundances of bile acids measured after 24 h incubations (3MC and 3MC + L) and axenic controls. Time course measurements of (B) bile acid abundances and (C) species abundance as shown by the inverse qPCR cycle thresholds (CT). Comparisons are shown between the 3MC and 3MC + L (with *L. acidophilus*) treated with the 0.1 mM bile acid mixture. Each data point shown in panels A-C represent the mean from a minimum of three biological replicates \pm 1 standard deviation. (D) Pearson's correlations between bacterial species and bile acid abundances; thicker lines correspond to greater correlation coefficients (cut-off below 0.85); red and grey colors correspond to positive and negative correlations, respectively.

profiles between the axenic and consortial treatments (Fig. 2a). The next piece of evidence was obtained from correlations between species and bile acids in the context of *a priori* knowledge of the metabolic reactions that were the basis for choosing each species in the model consortium (Fig. 2d). A possible mechanism for this could start with *B. obeum* conversion of cholic acid into a transient 7-keto intermediate, such as 7-oxodeoxycholic acid. A ketone intermediate was not identified by our bile-acid-targeting LC-MS metabolomics approach but that does not exclude the possibility of its existence. The next step could be achieved by the known genome encoded functions of *C. aerofaciens*, which contains *hdhB* (GenBank accession ZP_01773061)⁵⁵. This gene encodes for a 7 β -hydroxysteroid dehydrogenase (7 β -HSDH), known to catalyze a reaction that takes a 7-oxodeoxycholic acid to ursocholic acid⁵⁶. However, the *B. obeum* ATCC 29174 genome does not contain an oxidoreductase that is clearly annotated to catalyze our hypothesized reaction in this first step. *B. obeum* does contain a *baiA* gene (RUMOB_03494) that encodes a putative 7 α -dehydroxylase, but genes encoding for a 7 α -HSDH have yet to be identified. Yet our experiments clearly showed synthesis of ursocholic acid and we confirmed a required participation of *B. obeum*; hence, we concluded that a non-specific or previously unidentified oxidoreductase catalyzed this first step.

To test our hypothesis that *B. obeum* expresses enzymes that react with cholic acid (other than the known BaiA protein), we synthesized and employed a custom cholic acid photo affinity probe (CAP; cholic acid probe). This probe is a cholic acid derivative designed to bind and enrich proteins that can then be identified by MS-based proteomics (Fig. 3a). The results were a suite of proteins from each species in the consortium that were significantly enriched by the CAP (>10² fold-change; p-value < 0.001) (Table S2). Surprisingly, the *B. obeum* BaiA protein (RUMOB_03694) was not enriched by the CAP, indicating the possibility of an incorrect

annotation from homology of UniProt-KB A5ZWVO or lack of expression in these consortial conditions. We identified a suite of *B. obeum* proteins that were significantly enriched by the CAP and specific to the treatments corresponding to ursolic acid synthesis and the *B. obeum* axenic treatment. Of these, we focused on a pair of oxidoreductases as candidates for the hypothesized two-step, two-species reaction that lead to ursolic acid in our consortium. While they did not share strong homology with known 7α -HSDH proteins, they were annotated as enzymes that may catalyze the hypothesized alcohol-ketone inter-conversions (Fig. 3b). These CAP-binding proteins were annotated based on homology as an alcohol dehydrogenase (A5ZM66; *RUMOB*E_00083) and an alcohol-aldehyde dehydrogenase (A5ZNA3; *RUMOB*E_00470).




Figure 3. The multispecies synthesis hypothesis and cholic acid binding oxidoreductases. (A) The cholic acid photoaffinity probe (CAP) was synthesized and used to enrich proteins for mass spectrometry-based proteomics. (B) Of the proteins enriched by CAP (> 100 fold-change and $p < 0.001$), we identified two oxidoreductases annotated alcohol or alcohol-ketone dehydrogenases (ADH and ALDH, respectively). These proteins are *B. obeum* candidates for the hypothesized two-step, two-species mechanism (C) leading to the synthesis of ursolic acid. The abbreviations used to describe experimental treatments are as follows: Bo (*B. obeum*); Ca (*C. aerofaciens*); and Cs (*C. scindens*).

Implications toward obesity and

bariatric surgery. The proposed

mechanism for physiological effect for

Roux-en-Y gastric bypass surgery

(RYGB) are BRAVE “Bile flow

alteration, Reduction of gastric size

Anatomical gut re-arrangement, Vagal

manipulation, Enteric gut hormone

modulation⁵⁷. Hence, the GI tract of

patients that have undergone bariatric

surgery is a potential model system to

study bile acid metabolism/alterations

given that bile acid profiles change by increasing abundance of secondary bile acids⁴⁹. To

investigate the clinical relevance of ursolic acid, we leveraged access to a cohort of patients

that had undergone gastric bypass surgery. Targeted measurements of ursolic acid were

performed and compared in fecal samples collected from 24 patients that underwent RYGB

surgery: 10 patients with normal weight and 14 morbidly obese controls, which included those

scheduled for surgery⁴⁴. We found that the abundance of ursolic acid corresponded with

obesity and the success of gastric bypass surgical procedures (Fig. 4). Success was defined when

patients exhibited at least 50% excess weight loss and less than 20% regain. Ursolic acid

levels were significantly higher in the morbidly obese controls (pre-surgery) compared to

patients that had experienced successful gastric bypass surgery. There was no statistically




Figure 4. Normalized abundance of ursolic acid in feces of patients who had undergone gastric bypass surgery – Roux-en-Y gastric bypass (RYGB) – as compared to normal weight and obese controls. Unpaired two-tailed t-tests were used to infer a statistical difference between the means of the obese controls – a group that contained pre-operative patients – and those that experience successful RYGB ($p < 0.005$). Different ursolic acid abundances were also observed – albeit statistically less conclusive – between successful and unsuccessful RYGB patients ($p < 0.076$).

significant difference between the fecal abundance of ursocholic acid in the obese controls and the unsuccessful surgical patients.

DISCUSSION

The human gut microbiome is integral to human health and development^{58,59}. However, the function and composition of the human GI-tract ecosystem is complex⁶⁰, which often makes detailed studies of individual processes difficult. The use of model systems is a valuable approach to dissect complex biological functions. In particular, simplified model consortia gaining interest in microbiome research because they enable experimentalists to manage complexity by controlling multiple system components under defined treatments. The utility of simplified consortia, or bench-top microbiomes, has been demonstrated for a variety of human-associated communities^{61,62} and other complex microbial ecosystems related to plants⁶³, sediment/biofilms⁶⁴⁻⁶⁶ and marine habitats^{67,68}. Here, we developed a simple model microbial consortium that was specifically designed to investigate how the addition of a common probiotic (*L. acidophilus*) effects microbial interactions mediated through bile acid transformations. This study was not designed to directly inform microbial physiologies that should occur in the human GI-tract *in situ*. Rather, it was designed and successfully implemented for controlling the membership of microbial species and presence/absence of bile acids that are associated with human digestive systems. Our model bile acid consortium helped produce two major results. The first was that ursocholic acid was synthesized by the coordinated metabolism of a consortium and not by any single species included within this study. The second important finding was that probiotic, *L. acidophilus* quenched the observed multi-species interactions that resulted in secondary bile acid synthesis.

Ursocholic acid is the 7 beta-hydroxyepimer of cholic acid. It is rarely mentioned in the scientific literature and has been termed an “unusual secondary bile acid” as compared to more commonly studied metabolites such as deoxycholic and ursodeoxycholic acid⁶⁹. Previous studies have investigated ursocholic acid as a potential therapeutic to modulate the host’s synthesis of primary bile acids⁷⁰, or to improve the liver function of patients with primary biliary cirrhosis⁷¹ and reduction of bile cholesterol saturation⁷². In these previous studies, ursocholic acid was typically tested along with ursodeoxycholic acid and found to be notably less effective as a treatment for biliary cirrhosis⁷¹. Despite these therapeutic studies, little is known about the role that ursocholic acid plays in modulating human-microbe and/or microbe-microbe interactions.

The data derived from our clinical study showed that ursocholic acid is in fact present and abundant within the human GI-tract and its relative abundances change when drastic changes to microbiome occur (pre- and post- bariatric surgery)⁴⁴. Our limited understanding of the role that ursocholic acid plays in human health and specifically the host-microbiome interactions that lead to its production represent a major knowledge gap. This is punctuated by the fact that our current study – and a previous study⁷³ – have observed microbial synthesis of ursocholic acid and/or 7-oxodeoxycholic acid but not conclusively identified the genes and 7 α -HSDH proteins responsible.

Cataloguing the bacterial genes from the “sterolbiome” is an active area of research⁷⁴ that can yield new biological insight and help to improve human health by understanding how microbes modify chemical environments within the human GI tract. In this study, we hypothesized a multispecies chemical synthesis route in which *B. obeum* converts cholic acid into an intermediate ketone via a 7 α -HSDH-like reaction which is then proceeded by the known 7 β -HSDH reaction catalyzed by *C. aerofaciens*. Intraspecies 7-epimerization has been

demonstrated in *Clostridium limosum*⁷⁵ and *Clostridium absonum*⁷⁶, which express both the required enzymes, 7 α -HSDH and 7 β -HSDH. However, genes encoding for 7 α -HSDH, have yet to be identified in *B. obeum* and other bacteria such as an *Eggerthella* sp. known to express this protein⁷³. Yet, we conclusively found that a collaborative reaction between *B. obeum* and *C. aerofaciens* does occur, which highlights an increase in our understanding of bile acid metabolism of bacteria.

We hypothesized a 7-keto intermediate that was transferred between *B. obeum* and *C. aerofaciens* in the observed multispecies chemical synthesis route. We did not identify an intermediate such as 7-oxodeoxycholic acid in the supernatant of the samples and therefore cannot categorically confirm its existence. However, 7 α -HSDH mediated synthesis of 7-oxodeoxycholic acid has been previously observed in similar multi-step bile acid transformation processes⁵⁶. It is possible that *C. aerofaciens* has a high affinity uptake mechanism for the hypothesized 7-keto intermediate such that extracellular concentrations were below the detection limits of our LC- and GC-MS metabolite identification methods. Another point of uncertainty is whether the CAP-enriched alcohol dehydrogenase (A5ZM66; *RUMOB_E00083*) and alcohol-aldehyde dehydrogenase (A5ZNA3; *RUMOB_E00470*) were responsible for the hypothesized reactions. Certainly, other proteins were enriched by CAP (Table S2), yet these were the only *B. obeum* proteins annotated with an enzymatic function capable of alcohol-aldehyde interconversion. We cannot rule out the possibility that enriched proteins of unknown function participated in the observed reaction. However, there is some precedent for associating secondary bile acid synthesis genes with alcohol dehydrogenases. BaiA proteins from *C. scindens*, encoding for 3 α -HSDH proteins, have previously been shown to align well to short chain alcohol dehydrogenases in *Eubacterium* sp. Strain VPI 12708 and to alcohol/polyol

dehydrogenase genes^{77,78}. We chose to use *C. scindens* in the 3MC because it has genes that encode for Bai proteins and express HSDH proteins. In fact, the *C. scindens* reference proteome (VPI 12708) does contain a putative 7 α -HSDH (UniProtKB – Q03906); however, *C. scindens* abundances and correlation-based inferences from this study did not provide evidence of *C. scindens*' participation in the transformation of cholic acid to secondary acids. Our conclusion was that *C. scindens* played a minor role in the system and was largely outcompeted by other members.

Towards precision probiotics to complement bariatric surgery outcomes. The effect of probiotics on the human gut microbiome and the bile acid pools are particularly relevant due to the current epidemic of obesity and the comorbidities associated with high adiposity (high cholesterol, high blood pressure, diabetes)⁴². Hence, bariatric surgery is becoming more common as a treatment strategy. Yet knowledge gaps still exist with respect to how metabolites and microbes could play a role in successful outcomes. Here, we show that the abundance of ursocholic acid corresponds with the efficacy of gastric bypass surgery. This new knowledge about the role of specific probiotic strains and/or their metabolic products, are therefore leading towards promising novel treatments for patients undergoing bariatric surgery. It has already been shown that post-operative administration of *Lactobacillus* sp. improves weight loss and vitamin B absorption in RYGB patients⁴⁸. It is possible that the cessation of ursocholic acid production or increased abundances of *Lactobacillus* sp. could result in better control over weight loss. We also note that there is some precedent derived from mouse models for the idea that probiotics or introduction of non-adapted microbial taxa can modulate a hosts' microbiome⁷ and microbe-associated bile acid pool⁷⁹.

Conclusion. This current study was a fundamental investigation of microbial interactions and the role that a probiotic bacterium plays in modulating the synthesis of secondary bile acids. It was not intended to inform clinical practice. However, the results and conclusions presented establish an important idea related to broader microbiome sciences; microbial interactions are context dependent^{64,65} and the presence or absence of select species and/or metabolites can have a strong effect on the overall community-level function.

METHODS

Bacterial strains and cultivation. *Clostridium scindens* ATCC 35704, *Collinsella aerofaciens* ATCC 25986, *Blautia obeum* ATCC 29174 (formerly *Ruminococcus obeum*) and *Lactobacillus acidophilus* ATCC 4356 were grown under axenic conditions and in consortia on Lactobacilli MRS Broth (BD Difco, Houston, TX, USA). The primary treatment the addition of bile salts, equivalent mixtures of cholic and deoxycholic acid (Sigma-Aldrich 48305, St. Louis, MO, USA), supplemented to 0.1 mM. The secondary treatment was the presence and absence of probiotic, *Lactobacillus acidophilus* ATCC 4356 rendering either a 3-member (*L. acidophilus* negative) or 4-member (*L. acidophilus* positive) consortia. Anaerobic growth conditions were prepared by boiling the media and subsequently sparging with an 80% N₂, 10% H₂, 10% CO₂ gas mixture and transferring to 30 ml sealed Balch tubes under the same gas headspace prior to autoclaving. Each culture was inoculated to a starting OD_{630nm} = 0.077 ± 0.033 by each axenic cell suspension resulting in 1 serial passage of log phase cells; consortia were inoculated with an equivalent volume ratio mL. The optical density (OD_{630nm}) was measured over a 24 h period

using a Spectronic 20D+ spectrophotometer (ThermoSpectronic, Madison, WI, USA); each time point was sampled in triplicate via destructive sampling.

PCR quantification of gene target. Bacterial DNA was extracted from consortia and axenic culture using the MoBio (Carlsbad, CA, USA) PowerSoil DNA Isolation Kit following the manufacturer's protocol. A total volume of 5 μ L of undiluted consortia DNA or standard curve DNA was analyzed in triplicate with an Applied Biosystems 7500 fast instrument (Foster City, CA). Samples were analyzed in triplicate with the primers shown in Table S3 targeting *rpoB*. PCR reactions were run using the FAST cycling conditions: initial denaturation was done for 20 seconds at 95 °C followed by 40 cycles of denaturation (95 °C for 3 seconds), annealing (60 °C for 30 seconds). The output from the real-time PCR assays were C_T values that represent the PCR cycle at which the amplification crosses a given threshold (0.1). All C_T values in Table S4; data are plotted and analyzed as inverse C_T representing the relevant abundance^{66,80} assuming equal between species in the consortia.

Bile acid identification and quantification. Stock solutions of the cholic and deoxycholic acids (Steraloids Inc., Newport, RI, USA) were made in methanol (1 mg mL⁻¹) and were then pooled together and diluted in a series in 0.1% formic acid to generate a 7 pt of the calibration curve (0.0062, 0.025, 0.050, 0.1, 0.5 and 1 μ g mL⁻¹). An internal standard (23-nor-5 β -cholanolic acid-3 α , 12 α -diol) was added to the filtered media (0.2 μ m) collected from each microbial growth sample. Cold methanol (-20°C) was added at a ratio of 1:4 (filtrate:MeOH). The samples were mixed via vortexing, chilled at -20°C for 30 minutes and separated via centrifugation (1725 rpm, 10 minutes). The supernatant was removed and dried and then re-suspended in 0.1% formic acid in

deionized water solution. These samples were analyzed on a Waters nano-Acquity UPLC system (Milford, MA, USA) configured for direct 5 μ L sample injections onto an in-house packed fused silica column (360 μ m o.d. x 150 μ m i.d. x 30 cm long; Polymicro Technologies Inc., Phoenix, AZ, USA) containing Waters HSS T3 media (1.8 μ m particle size). A flow of 600 nL min⁻¹ was maintained using mobile phases consisting of (A) 0.1% formic acid in water and (B) 0.12 % formic acid and 5 mM ammonium acetate in methanol with the following gradient profile (min, %B): 0, 1; 5, 1; 10, 65; 59, 99; 60, 1. Total run time including column re-equilibration was 75 min. Mass spectrometry (MS) analysis was performed using an Agilent model 6490 triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA, USA) outfitted with a custom nano-electrospray ionization interface built using 150 μ m o.d. x 20 μ m i.d. chemically etched fused silica⁸¹. The hexabore ion transfer tube temperature and spray voltage were held at 200°C and -4.0 kV, respectively. Data were acquired in negative ion mode for 75 min from sample injection using a dwell time of 200 μ s, fragmentation of 380 volts, and collision energy of 10 volts. Selected reaction monitoring (SRM) transitions were acquired as shown in supplementary Table S5. Ursocholic acid was identified as an unknown in the initial LC-MS trials. After fractionation and purification, we isolated the unknown and verified that it was ursocholic acid via NMR and ion mobility mass spectrometry analyses. Authentic ursocholic acid was purchased from Toronto Research Chemicals (N. York, Ontario, Canada). Comprehensive details of these procedures are provided in the supplementary materials.

Untargeted Metabolomics. The spent media was dried, chemically derivatized and analyzed by GC-MS as previously reported⁸². GC-MS raw data files collected by GC-MS were processed using the Metabolite Detector software, version 2.5 beta⁸³. Agilent .D files were converted to

netCDF format using Agilent Chemstation (Agilent, Santa Clara, CA, USA) and then converted to binary files using Metabolite Detector. Samples were aligned chromatographically across all analyses after deconvolution. Metabolites were identified by matching experimental spectra to a Pacific Northwest National Laboratory (PNNL) augmented version of FiehnLib⁸⁴. This library has spectra and validated retention indices for over 850 metabolites. In order to minimize errors in deconvolution and identification, all metabolite identifications were manually validated after automated data-processing.

Bile acid photoaffinity probes and proteomics. Custom photoaffinity probes were synthesized as derivatives of cholic and deoxycholic acid for this study as described in detail within the supplementary materials. Bacterial lysate samples were normalized to 500 μ L 1.8 mg/mL proteome in PBS buffer. Cholic acid photoaffinity probe (CAP) or an equal volume of DMSO control was incubated with proteome for 60 min at 37 °C. Final DMSO concentration was 1%. Samples were exposed to UV light (wavelength: 365nm; 115V, 15W) using a Fisher UVP95 lamp (Fisher Scientific, Hampton, NH, USA) for 7 minutes on ice. Subsequent to UV irradiation, the samples were subjected to click chemistry, with final concentrations of reagents being: biotin-azide (60 μ M) in DMSO, sodium ascorbate (10 mM), THPTA (4 mM), and CuSO₄ (8 mM). Each reagent was added individually in that sequence, vortexed, centrifuged, and incubated at room temperature in the dark for 90 min. 800 μ L of pre-chilled MeOH was then added to each sample and incubated at -80 °C freezer for 30 min to induce protein precipitation. Samples were centrifuged at 14,000 x g at 4°C for 5 min. The supernatant was discarded, and the pellet was allowed to air-dry for 5 min. Samples were reconstituted and sonicated in 520 μ L SDS (1.2%) in PBS; followed by incubation at 95 °C for 2 min. Samples were centrifuged at 14,000 x

g for 4 min at room temperature. Protein concentrations were determined via BCA assay and samples were normalized to a volume of 500 μ L at 1.2 mg/mL. Trypsin digestion was performed on protein bound to 100 μ L Streptavidin-agarose beads. Peptides were reconstituted by adding 40 μ l of 25 mM NH_4HCO_3 and heating the samples at 37°C for 5 min. Samples were transferred to ultracentrifuge tubes and were centrifuged at 100,000 x g to remove debris. 25 μ L was added to glass vials for storage at -20 °C until analysis. All proteomics samples prepared for LC-MS were analyzed using a Velos Orbitrap MS as previously described^{85,86}.

Clinical data and experimentation. Fecal samples were collected from patients at the Mayo Clinic, Scottsdale, AZ, USA. The metabolomics assays were performed at the Pacific Northwest National Laboratory by the methods described above. The experimental design has been previously described⁴⁴ and was approved by The Institutional Review Boards of Mayo Clinic and Arizona State University (IRB# 10-008725).

Statistics. Analysis and graphing was performed in R⁸⁷ making use of the ‘vegan’⁸⁸ and ‘igraph’⁸⁹ packages, along with many packages in the Tidyverse⁹⁰. The adonis test (permutation MANOVA) was used to partition a matrix of Euclidean distances between global metabolite samples based on bile acid and probiotic treatments. An unpaired two-tailed Student’s t-test was used to compare fecal ursocholic acid measurements between treatment groups. Linear models were fit to the log of the exponential growth phase of microbial consortia, and for each regression, the goodness of fit and the probability of observing a similar slope if the true slope coefficient was zero was reported. Global proteomics was used to identify proteins enriched by the CAP probes, by selecting proteins with a fold-change increase of >100 and a t-test p-value of

< 0.001. The methods for all hypothesis testing and descriptive statistical procedures are included in the R markdown supplied for this study.

Data Repositories and Reproducibility. The raw data sets for this study along with the R scripts used for analysis and graphing are available from the Open Science Framework (OSF) under the name “Bile Acids Consortia” at <https://osf.io/5meyd/>. The mass spectrometry proteomics data have been deposited to ProteomeXchange with the dataset identifier PXD008617.

ACKNOWLEDGMENT

This research was supported by the Microbiomes in Transition (*MinT*) Initiative, a Laboratory Directed Research and Development (LDRD) Program of Pacific Northwest National Laboratory (PNNL). Measurements of bile acids in samples from the human clinical trial were supported by the PNNL LDRD Program via the Signature Discovery Initiative. Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R01DK090379. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Metabolomics measurements and chemical characterization of ursocholic acid were performed in the Environmental Molecular Sciences Laboratory (user project 49356), a national scientific user facility sponsored by the Department of Energy Office of Biological and Environmental Research, located at PNNL. PNNL is operated for the DOE by Battelle under contract no. DE-AC05-76RLO-1830. Specific acknowledgments are given to Heather Brewer, Athena Schepmoes, Rose Perry and Erika Zink for their technical contributions.

504

505 **CONFLICT OF INTEREST**

506 The authors have no conflict of interest to declare.

507 **REFERENCES CITED**

- 508 1 Carballa, M., Regueiro, L. & Lema, J. M. Microbial management of anaerobic digestion:
509 exploiting the microbiome-functionality nexus. *Curr Opin Biotech* **33**, 103-111 (2015).
- 510 2 Simon, G. L. & Gorbach, S. L. The human intestinal microflora. *Digest Dis Sci* **31**, 147-162 (1986).
- 511 3 Brown, J. M. & Hazen, S. L. Microbial modulation of cardiovascular disease. *Nat Rev Microbiol*
512 (2018).
- 513 4 Foster, J. A. & Neufeld, K.-A. M. Gut-brain axis: how the microbiome influences anxiety and
514 depression. *Trends Neurosci* **36**, 305-312 (2013).
- 515 5 Bach, J.-F. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. *Nat*
516 *Rev Immunol* (2017).
- 517 6 Schmidt, T. S., Raes, J. & Bork, P. The human gut microbiome: from association to modulation.
518 *Cell* **172**, 1198-1215 (2018).
- 519 7 Martin, F. P. J. *et al.* Probiotic modulation of symbiotic gut microbial-host metabolic interactions
520 in a humanized microbiome mouse model. *Mol Sys Biol* **4**, 157 (2008).
- 521 8 Kang, D.-W. *et al.* Microbiota Transfer Therapy alters gut ecosystem and improves
522 gastrointestinal and autism symptoms: an open-label study. *Microbiome* **5**, 10 (2017).
- 523 9 McFarland, L. V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea
524 and the treatment of *Clostridium difficile* disease. *Am J Gastroenterol* **101**, 812-822 (2006).
- 525 10 AlFaleh, K. & Anabrees, J. Probiotics for prevention of necrotizing enterocolitis in preterm
526 infants. *Evid-Based Child Health: A Cochrane Rev J* **9**, 584-671 (2014).
- 527 11 Baquero, F. & Nombela, C. The microbiome as a human organ. *Clin Microbiol Inf* **18**, 2-4 (2012).
- 528 12 Bron, P. A., van Baarlen, P. & Kleerebezem, M. Emerging molecular insights into the interaction
529 between probiotics and the host intestinal mucosa. *Nat Rev Microbiol* **10**, 66-78 (2012).
- 530 13 Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the
531 immune system. *Science* **336**, 1268-1273 (2012).
- 532 14 Gilbert, J. A., Krajmalnik-Brown, R., Porazinska, D. L., Weiss, S. J. & Knight, R. Toward effective
533 probiotics for autism and other neurodevelopmental disorders. *Cell* **155**, 1446-1448 (2013).
- 534 15 Pandey, G., Pandey, A. K., Pandey, S. & Pandey, B. Microbiota in Immune Pathogenesis and the
535 Prospects for Pre and Probiotic Dietetics in Psoriasis. *Biomed Res J*, 220.
- 536 16 Vaghef-Mehrabany, E. *et al.* Probiotic supplementation improves inflammatory status in
537 patients with rheumatoid arthritis. *Nutrition* **30**, 430-435 (2014).
- 538 17 Zhang, Y. *et al.* Effects of probiotic type, dose and treatment duration on irritable bowel
539 syndrome diagnosed by Rome III criteria: a meta-analysis. *BMC Gastroenterol* **16**, 62 (2016).
- 540 18 Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol*
541 **16**, 341-352 (2016).
- 542 19 Bäumler, A. J. & Sperandio, V. Interactions between the microbiota and pathogenic bacteria in
543 the gut. *Nature* **535**, 85-93 (2016).
- 544 20 Haywood, B. A. *et al.* Probiotic supplementation reduces the duration and incidence of
545 infections but not severity in elite rugby union players. *J Sci Med Sport* **17**, 356-360 (2014).

546 21 King, S., Glanville, J., Sanders, M. E., Fitzgerald, A. & Varley, D. Effectiveness of probiotics on the
547 duration of illness in healthy children and adults who develop common acute respiratory
548 infectious conditions: a systematic review and meta-analysis. *Brit J Nutr* **112**, 41-54 (2014).
549 22 Lomax, A. & Calder, P. Probiotics, immune function, infection and inflammation: a review of the
550 evidence from studies conducted in humans. *Curr Pharm Design* **15**, 1428-1518 (2009).
551 23 Fooks, L. & Gibson, G. Probiotics as modulators of the gut flora. *Brit J Nutr* **88**, s39-s49 (2002).
552 24 Hemarajata, P. & Versalovic, J. Effects of probiotics on gut microbiota: mechanisms of intestinal
553 immunomodulation and neuromodulation. *Ther Adv Gastroenter*, 1756283X12459294 (2012).
554 25 Ohland, C. L. & MacNaughton, W. K. Probiotic bacteria and intestinal epithelial barrier function.
555 *Am J Physiol-Gastr L* **298**, G807-G819 (2010).
556 26 Begley, M., Gahan, C. G. & Hill, C. The interaction between bacteria and bile. *FEMS Microbiol Rev*
557 **29**, 625-651 (2005).
558 27 Ridlon, J. M., Kang, D.-J. & Hylemon, P. B. Bile salt biotransformations by human intestinal
559 bacteria. *J Lipid Res* **47**, 241-259 (2006).
560 28 Monte, M. J., Marin, J., Antelo, A. & Vazquez-Tato, J. Bile acids: chemistry, physiology, and
561 pathophysiology. *World J Gastroenterol* **15**, 804-816 (2009).
562 29 Kuipers, F., Bloks, V. W. & Groen, A. K. Beyond intestinal soap [mdash] bile acids in metabolic
563 control. *Nat Rev Endocrinol* **10**, 488-498 (2014).
564 30 Attili, A., Angelico, M., Cantafora, A., Alvaro, D. & Capocaccia, L. Bile acid-induced liver toxicity:
565 relation to the hydrophobic-hydrophilic balance of bile acids. *Med Hypotheses* **19**, 57-69 (1986).
566 31 Louis, P., Hold, G. L. & Flint, H. J. The gut microbiota, bacterial metabolites and colorectal cancer.
567 *Nat Rev Microbiol* **12**, 661-672 (2014).
568 32 Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S. & Moschetta, A. Microbiota modification
569 with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in
570 mice. *Cell Rep* **7**, 12-18 (2014).
571 33 Kawamata, Y. *et al.* AG protein-coupled receptor responsive to bile acids. *J Biol Chem* **278**, 9435-
572 9440 (2003).
573 34 Thomas, C. *et al.* TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metabol*
574 **10**, 167-177 (2009).
575 35 Islam, K. S. *et al.* Bile acid is a host factor that regulates the composition of the cecal microbiota
576 in rats. *Gastroenterol* **141**, 1773-1781 (2011).
577 36 Kurdi, P., Kawanishi, K., Mizutani, K. & Yokota, A. Mechanism of growth inhibition by free bile
578 acids in lactobacilli and bifidobacteria. *J Bacteriol* **188**, 1979-1986 (2006).
579 37 Ridlon, J. M., Kang, D. J., Hylemon, P. B. & Bajaj, J. S. Bile acids and the gut microbiome. *Curr*
580 *Opin Gastroenterol* **30**, 332 (2014).
581 38 Maier, T. V. *et al.* Impact of Dietary Resistant Starch on the Human Gut Microbiome,
582 Metaproteome, and Metabolome. *mBio* **8**, e01343-01317 (2017).
583 39 Sagar, N. M., Cree, I. A., Covington, J. A. & Arasaradnam, R. P. The interplay of the gut
584 microbiome, bile acids, and volatile organic compounds. *Gastroent Res Pract* **2015** (2015).
585 40 Daniel, H. *et al.* High-fat diet alters gut microbiota physiology in mice. *ISME J* **8**, 295-308 (2014).
586 41 Nie, Y.-f., Hu, J. & Yan, X.-h. Cross-talk between bile acids and intestinal microbiota in host
587 metabolism and health. *J Zhejiang University* **16**, 436 (2015).
588 42 Swinburn, B. A. *et al.* The global obesity pandemic: shaped by global drivers and local
589 environments. *Lancet* **378**, 804-814 (2011).
590 43 Buchwald, H. & Oien, D. M. Metabolic/bariatric surgery worldwide 2008. *Obes Surg* **19**, 1605-
591 1611 (2009).
592 44 Ilhan, Z. E. *et al.* Distinctive microbiomes and metabolites linked with weight loss after gastric
593 bypass, but not gastric banding. *ISME J* (2017).

594 45 Cottam, D. R., Atkinson, J., Anderson, A., Grace, B. & Fisher, B. A case-controlled matched-pair
595 cohort study of laparoscopic Roux-en-Y gastric bypass and Lap-Band® patients in a single US
596 center with three-year follow-up. *Obes Surg* **16**, 534-540 (2006).

597 46 Buchwald, H. *et al.* Bariatric surgery: a systematic review and meta-analysis. *Jama* **292**, 1724-
598 1737 (2004).

599 47 Sweeney, T. E. & Morton, J. M. The human gut microbiome: a review of the effect of obesity and
600 surgically induced weight loss. *JAMA Surg* **148**, 563-569 (2013).

601 48 Woodard, G. A. *et al.* Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a
602 prospective randomized trial. *J Gastrointest Surg* **13**, 1198-1204 (2009).

603 49 Albaugh, V. L. *et al.* Early increases in bile acids post Roux-en-Y gastric bypass are driven by
604 insulin-sensitizing, secondary bile acids. *J Clin Endocrinol Metab* **100**, E1225-E1233 (2015).

605 50 Ryan, K. K. *et al.* FXR is a molecular target for the effects of vertical sleeve gastrectomy. *Nature*
606 **509**, 183 (2014).

607 51 Cayuela, C. & Juste, C. Isolates from Normal Human Intestinal Flora but not Lactic Acid Bacteria
608 Exhibit 7 α -and 7 β -Hydroxysteroid Dehydrogenase Activities. *Microb Ecol Health D* **16** (2004).

609 52 Hirano, S. & Masuda, N. Characterization of NADP-dependent 7 beta-hydroxysteroid
610 dehydrogenases from *Peptostreptococcus productus* and *Eubacterium aerofaciens*. *Appl Environ*
611 *Microbiol* **43**, 1057-1063 (1982).

612 53 Floch, M. H., Binder, H. J., Filburn, B. & Gershengoren, W. The effect of bile acids on intestinal
613 microflora. *The American journal of clinical nutrition* **25**, 1418-1426 (1972).

614 54 Binder, H., Filburn, B. & Floch, M. Bile acid inhibition of intestinal anaerobic organisms. *The*
615 *American journal of clinical nutrition* **28**, 119-125 (1975).

616 55 Liu, L., Aigner, A. & Schmid, R. D. Identification, cloning, heterologous expression, and
617 characterization of a NADPH-dependent 7 β -hydroxysteroid dehydrogenase from *Collinsella*
618 *aerofaciens*. *Appl Microbiol Biotechnol* **90**, 127-135 (2011).

619 56 Ferrandj, E. E. *et al.* In search of sustainable chemical processes: cloning, recombinant
620 expression, and functional characterization of the 7 α -and 7 β -hydroxysteroid dehydrogenases
621 from *Clostridium absonum*. *Appl Environ Microbiol* **95**, 1221-1233 (2012).

622 57 Li, J. V. *et al.* Metabolic surgery profoundly influences gut microbial–host metabolic cross-talk.
623 *Gut* **60**, 1214-1223 (2011).

624 58 Yatsunenkov, T. *et al.* Human gut microbiome viewed across age and geography. *Nature* **486**, 222
625 (2012).

626 59 Huttenhower, C. *et al.* Structure, function and diversity of the healthy human microbiome.
627 *Nature* **486**, 207 (2012).

628 60 Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. & Knight, R. Diversity, stability and
629 resilience of the human gut microbiota. *Nature* **489**, 220 (2012).

630 61 James, G. A. *et al.* Microsensor and transcriptomic signatures of oxygen depletion in biofilms
631 associated with chronic wounds. *Wound Rep Regen* **24**, 373-383 (2016).

632 62 Shu, M., Wong, L., Miller, J. & Sissons, C. Development of multi-species consortia biofilms of oral
633 bacteria as an enamel and root caries model system. *Arch Oral Biol* **45**, 27-40 (2000).

634 63 Niu, B., Paulson, J. N., Zheng, X. & Kolter, R. Simplified and representative bacterial community
635 of maize roots. *Proc Nat Acad Sci* **114**, E2450-E2459 (2017).

636 64 Khan, N. *et al.* Phenotypic responses to interspecies competition and commensalism in a
637 naturally-derived microbial co-culture. *Sci Rep* **8**, 297 (2018).

638 65 Bernstein, H. C. *et al.* Indirect interspecies regulation: transcriptional and physiological
639 responses of a cyanobacterium to heterotrophic partnership. *MSystems* **2**, e00181-00116
640 (2017).

641 66 Cole, J. K. *et al.* Phototrophic biofilm assembly in microbial-mat-derived unicyanobacterial
642 consortia: model systems for the study of autotroph-heterotroph interactions. *Front Microbiol* **5**,
643 109 (2014).
644 67 Beliaev, A. S. *et al.* Inference of interactions in cyanobacterial–heterotrophic co-cultures via
645 transcriptome sequencing. *ISME J* **8**, 2243 (2014).
646 68 Boetius, A. *et al.* A marine microbial consortium apparently mediating anaerobic oxidation of
647 methane. *Nature* **407**, 623 (2000).
648 69 Nakashima, T. *et al.* A paucity of unusual trihydroxy bile acids in the urine of patients with
649 severe liver diseases. *Hepatology* **29**, 1518-1522 (1999).
650 70 Tint, G. S. *et al.* Metabolism of ursocholic acid in humans: Conversion of ursocholic acid to
651 deoxycholic acid. *Hepatology* **15**, 645-650 (1992).
652 71 Batta, A. K., Salen, G. & Abroon, J. Ursocholic acid, a hydrophilic bile acid, fails to improve liver
653 function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid. *Am J*
654 *Gastroenterol* **92** (1997).
655 72 Loria, P. *et al.* Effect of ursocholic acid on bile lipid secretion and composition. *Gastroenterol* **90**,
656 865-874 (1986).
657 73 Mythen, S. M., Devendran, S., Méndez-García, C., Cann, I. & Ridlon, J. M. Targeted synthesis and
658 characterization of a gene-cluster encoding NAD (P) H-dependent 3 α -, 3 β -, and 12 α -
659 hydroxysteroid dehydrogenases from Eggerthella CAG: 298, a gut metagenomic sequence. *Appl*
660 *Environ Microbiol*, AEM. 02475-02417 (2018).
661 74 Ridlon, J. M. & Bajaj, J. S. The human gut sterolbiome: bile acid-microbiome endocrine aspects
662 and therapeutics. *Acta Pharm Sin B* **5**, 99-105 (2015).
663 75 Sutherland, J. D. & Macdonald, I. A. The metabolism of primary, 7-oxo, and 7 beta-hydroxy bile
664 acids by *Clostridium absonum*. *J Lipid Res* **23**, 726-732 (1982).
665 76 Macdonald, I. A. & Roach, P. D. Bile salt induction of 7 α - and 7 β -hydroxysteroid dehydrogenases
666 in *Clostridium absonum*. *Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism* **665**,
667 262-269 (1981).
668 77 Mallonee, D. H., Lijewski, M. A. & Hylemon, P. B. Expression in *Escherichia coli* and
669 characterization of a bile acid-inducible 3 α -hydroxysteroid dehydrogenase from *Eubacterium* sp.
670 strain VPI 12708. *Curr Microbiol* **30**, 259-263 (1995).
671 78 White, W., Franklund, C., Coleman, J. & Hylemon, P. Evidence for a multigene family involved in
672 bile acid 7-dehydroxylation in *Eubacterium* sp. strain VPI 12708. *J Bacteriol* **170**, 4555-4561
673 (1988).
674 79 Martin, F. P. J. *et al.* A top-down systems biology view of microbiome-mammalian metabolic
675 interactions in a mouse model. *Mol Sys Biol* **3**, 112 (2007).
676 80 Habibi, A. *et al.* The effects of vitrification on gene expression in mature mouse oocytes by
677 nested quantitative PCR. *Journal of assisted reproduction and genetics* **27**, 599-604 (2010).
678 81 Kelly, R. T. *et al.* Chemically etched open tubular and monolithic emitters for nanoelectrospray
679 ionization mass spectrometry. *Anal Chem* **78**, 7796-7801 (2006).
680 82 Kim, Y.-M. *et al.* Diel metabolomics analysis of a hot spring chlorophototrophic microbial mat
681 leads to new hypotheses of community member metabolisms. *Front Microbiol* **6**, 209 (2015).
682 83 Hiller, K. *et al.* MetaboliteDetector: comprehensive analysis tool for targeted and nontargeted
683 GC/MS based metabolome analysis. *Anal Chem* **81**, 3429-3439 (2009).
684 84 Kind, T. *et al.* FiehnLib: mass spectral and retention index libraries for metabolomics based on
685 quadrupole and time-of-flight gas chromatography/mass spectrometry. *Anal Chem* **81**, 10038-
686 10048 (2009).
687 85 Bernstein, H. C. *et al.* Multi-omic dynamics associate oxygenic photosynthesis with nitrogenase-
688 mediated H₂ production in *Cyanothece* sp. ATCC 51142. *Sci Rep* **5** (2015).

689 86 Sadler, N. C. *et al.* Dinitrogenase-Driven Photobiological Hydrogen Production Combats
690 Oxidative Stress in *Cyanothece* sp. Strain ATCC 51142. *Appl Environ Microbiol* **82**, 7227-7235
691 (2016).
692 87 Team, R. C. R: A language and environment for statistical computing. (2013).
693 88 Oksanen, J. *et al.* The vegan package. *Community ecology package* **10**, 631-637 (2007).
694 89 Csardi, G. & Nepusz, T. The igraph software package for complex network research. *InterJournal*,
695 *Complex Systems* **1695**, 1-9 (2006).
696 90 Wickham, H. Tidyverse: Easily install and load 'tidyverse' packages. *R package version 1* (2017).
697